Glycated Proteins, Glycine, Acetate, and Monounsaturated Fatty Acids May Act as New Biomarkers to Predict the Progression of Type 2 Diabetes: Secondary Analyses of a Randomized Controlled Trial.
Francisco CanetJacob J ChristensenVíctor Manuel VíctorKristin S HustadInger OttestadAmanda RundbladThomas SætherKnut Tomas DalenStine M UlvenKirsten B HolvenVibeke H Telle-HansenPublished in: Nutrients (2022)
Food protein or food-derived peptides may regulate blood glucose levels; however, studies have shown inconsistent results. The aim of the present study was to characterize subgroups of individuals with increased risk of type 2 diabetes (T2D) and to investigate the cardiometabolic effects of fish protein in the same subgroups. We first divided participants into high insulin iAUC and low insulin iAUC subjects based on their insulin incremental area under the curve (iAUC) levels after a 2 h oral glucose tolerance test (OGTT), and secondly based on whether they had received 5.2 g salmon fish protein or placebo for 8 weeks, in a previously conducted randomized controlled trial (RCT). We then profiled these groups by analyzing plasma metabolomics and peripheral blood mononuclear cell (PBMC) gene expression. Compared to the low insulin iAUC group, the high insulin iAUC group had higher plasma concentrations of monounsaturated fatty acids (MUFAs) and glycated proteins (GlycA) and lower concentrations of glycine and acetate. After intervention with fish protein compared to placebo, however, only acetate was significantly increased in the low insulin iAUC group. In conclusion, we identified metabolic biomarkers known to be associated with T2D; also, intervention with fish protein did not affect cardiometabolic risk markers in subgroups with increased risk of T2D.
Keyphrases
- type diabetes
- randomized controlled trial
- glycemic control
- gene expression
- blood glucose
- peripheral blood
- fatty acid
- protein protein
- amino acid
- binding protein
- dna methylation
- study protocol
- small molecule
- systematic review
- clinical trial
- single cell
- mass spectrometry
- blood pressure
- mesenchymal stem cells
- adipose tissue
- risk assessment
- placebo controlled
- open label